Xenon Pharmaceuticals reported a net loss of $323.5 million for the nine months ended September 30, 2026, compared to $240.6 million in the prior year, driven by increased R&D spending on its lead candidate azetukalner. The company significantly strengthened its balance sheet, ending the period with $1.15 billion in cash, cash equivalents, and marketable securities following substantial common share issuances.
Xenon Pharmaceuticals reported Q3 2026 financial results, highlighting the submission of its New Drug Application (NDA) for azetukalner in focal seizures to the FDA in September 2026. The company ended the quarter with $1.2 billion in cash and marketable securities, providing a projected cash runway into 2029 as it prepares for topline Phase 3 MDD data in December 2026.
Term
Q3 2026
“We've made significant progress advancing azetukalner with our recent NDA submission to the FDA for focal seizures and through ongoing scientific exchange opportunities. We continue to have great confidence in azetukalner’s product profile in epilepsy based on strong efficacy and consistent safety across more than 1,500 patient-years of data, which has been reiterated in conversations with both epileptologists and neurologists.”
Ian Mortimer, President and Chief Executive Officer
Xenon Pharmaceuticals CFO Thomas Patrick Kelly Buys $560K of Stock
Thomas Patrick Kelly, CFO, bought 15,000 shares of Xenon Pharmaceuticals Inc. at $37.32 a share, worth $560K in total on Sep 30, 2026. Shares held after the trade: 15,000.
Xenon Pharmaceuticals President & CEO Ian Mortimer Buys $1.12M of Stock
Ian Mortimer, President & CEO, bought 30,000 shares of Xenon Pharmaceuticals Inc. at $37.38 a share, worth $1.12M in total on Sep 30, 2026. Shares held after the trade: 49,923 (+150.6%).